Velocity Clinical Research Welcomes New Leadership
Velocity Clinical Research, a distinguished site organization in clinical research, recently announced the appointment of Andrew (Drew) Reina as its Chief Revenue Officer (CRO), effective immediately. This strategic move marks a significant milestone in Velocity's journey as it seeks to strengthen its partnerships within the clinical research ecosystem.
Drew Reina’s Impressive Background
Drew Reina joins Velocity after an impactful tenure at Fortrea, a prominent contract research organization (CRO). His experience in driving growth strategies and business development at Fortrea positions him well to enhance Velocity's approach to engaging with Sponsors and CRO partners. His deep understanding of the CRO landscape is expected to support Velocity in achieving its ambitious growth targets.
Strategic Goals Moving Forward
In his new role, Drew Reina will focus on leading revenue and partnership strategies for Velocity, striving to align patient recruitment expectations with the operational needs of biotech companies and smaller Sponsors. This collaboration aims to elevate the standard of clinical trial execution, ensuring that stakeholders work together more seamlessly than ever before.
Comments from Leadership
Paul Evans, PhD, President & CEO of Velocity, expressed enthusiasm about Drew's appointment, stating, "This has been a challenging year for clinical research. Andrew's experience at Fortrea brings deep CRO-centric leadership to our senior team, and his appointment is key in positioning Velocity as a strategic partner for biotech and pharma companies."
Drew’s Vision for Velocity
Adding to that, Drew Reina said, "I'm honored to join such a talented team and organization. Velocity is recognized for creating an integrated site network that stands out in delivering quality clinical research. Given the complexities of trial execution today, I look forward to leveraging our strengths to meet the evolving needs of our clients."
The Importance of Integrated Clinical Research
Drew highlighted that clinical research Sponsors and CROs increasingly rely on multisite clinical research corporations (MCRCs) to optimize trial timelines and reduce the burden on sites and patients. Velocity has established itself as a leader in this regard and aims to continually adapt to the dynamic clinical research environment.
Drew's Extensive Experience
With over two decades in the clinical research field, Drew most recently held the position of Vice President and Head of Sales at Fortrea. His role involved leading a successful commercial team in executing a variety of clinical trials across multiple therapeutic areas. Previously, he served as Vice President for PPD's Biopharma segment, managing a vast portfolio that encompassed strategic partnerships and alliance management.
Fostering Growth Through Partnership
In his role at Velocity, Drew intends to cultivate growth through effective partnerships, drive business development, and ensure exceptional site performance. He emphasizes the necessity of aligning operational excellence with the goals of Sponsors and CROs to deliver superior outcomes for clinical trials.
About Velocity Clinical Research
Velocity Clinical Research is a premier integrated site organization that delivers innovative solutions in clinical trials. With more than 70 sites and a substantial number of investigators, Velocity collaborates with pharmaceutical and biotechnology companies to advance new therapies and medical products that aim to enhance human health.
Innovative Technological Solutions
Moreover, Velocity operates a technology hub in India, where it is working to innovate clinical research by harnessing advanced systems and extensive data. This commitment to technology aims to enhance efficiency and accuracy in clinical trials, ultimately improving patient care and data quality.
Media Contact Information
For more details, media inquiries can be directed to Katie Evans at kevans@velocityclinical.com.
Frequently Asked Questions
Who is the new Chief Revenue Officer of Velocity Clinical Research?
Andrew (Drew) Reina has been appointed as the new Chief Revenue Officer.
What prior experience does Drew Reina bring?
Drew Reina has over two decades in global clinical research, previously serving as Vice President at Fortrea and PPD's Biopharma segment.
What are Drew Reina's responsibilities at Velocity?
He will focus on revenue and partnership strategy, patient recruitment, and aligning business operations to meet Sponsor and CRO expectations.
What is Velocity Clinical Research known for?
Velocity is recognized for its leading role in integrated site solutions for clinical trials, providing exceptional quality and operational excellence.
How does Velocity utilize technology in clinical research?
Velocity employs its technology hub in India to innovate and improve clinical research operations through data-driven insights.
